medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (5)


Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection

Lieveld FI, Swaans N, Newsum AM, Ho CKY, Schinkel J, Molenkamp R, van der Meer JTM, Arends JE, Hoepelman AIM, Wensing AMJ, Siersema PD, van Erpecum KJ, Boland GJ

Idioma: Ingles.
Referencias bibliográficas: 32
Paginas: 696-704
Archivo PDF: 214.54 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J Hepatol 2014; 62: 1008-14.

  2. Sulkowski M, Benhamou Y. Therapeutic issues in HIV/HCVcoinfected patients. J Viral Hepat 2007; 14: 371-86.

  3. Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008; 62: 1-4.

  4. Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, Wyckmans Y, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the european region. Antiviral Res 2015; 116: 10-6.

  5. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.

  6. Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 2011; 18: 608-18.

  7. De Luca A, Di Giambenedetto S, Presti AL, Sierra S, Prosperi M, Cella E, Giovanetti M, et al. Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 2015. Open Forum Infect Dis 2015; 2: ofv043.

  8. Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010; 54: 5288-97.

  9. Susser S, Schelhorn S, Lange C, Welsch C, Vermehren J, Perner D, Füller C, et al. Ultratiefe pyrosequenz-analyse (UDPS) von neu beschriebenen seltenen resistenzvarianten der hepatitis C virus NS3 protease bei patienten, die mit telaprevir oder boceprevir behandelt wurden. Z Gastroenterol 2012; 50 - K052.

  10. Kieffer TL, George S. Resistance to hepatitis C virus protease inhibitors. Current opinion in virology 2014; 8: 16-21.

  11. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. The Lancet 2014; 384: 1756-65.

  12. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015; 63: 564-72.

  13. Ogishi M, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, et al. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: Comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in japan. PLoS One 2015; 10: e0119145.

  14. Ehret R, Neifer S, Walter H, Baumgarten A, Obermeier M. Appearance of NS3 Q80K mutation in HCV genotype 1a monoor HIV/HCV co-infected patients in a berlin laboratory. J Int AIDS Soc 2014; 17(4, Suppl. 3): 19741.

  15. Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, Sidella L, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in italy. J Antimicrob Chemother 2012; 67: 984-7.

  16. van Soest H, van der Schaar PJ, Koek GH, de Vries RA, van Ooteghem NA, van Hoek B, Drenth JP, et al. No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis 2010; 42: 496-502.

  17. Poveda E, Wyles DL, Mena Á, Pedreira JD, Castro-Iglesias Á, Cachay E. Update on hepatitis C virus resistance to directacting antiviral agents. Antiviral Res 2014; 108: 181-91.

  18. Nevot M, Boesecke C, Parera M, Andrés C, Franco S, Revollo B, Ingiliz P, et al. Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients. J Viral Hepat 2014; 21: e19-e28.

  19. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136: 1609-17.

  20. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, et al. Increase in HCV incidence among men who have sex with men in amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230-8.

  21. Bagaglio S, Uberti-Foppa C, Messina E, Merli M, Hasson H, Andolina A, Galli A, et al. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV infected patients. Clin Microbiol Infect 2015; S1198-743X(15)01033-2.

  22. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015.

  23. Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a scottish cohort. J Clin Virol 2015; 65: 50-3.

  24. Jabara CB, Hu F, Mollan KR, Williford SE, Menezes P, Yang Y, Eron JJ, et al. Hepatitis C virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother 2014; 58: 6079-92.

  25. Lin M, Charlton A, Rouster S, Zamor P, Sherman K. Hepatitis C virus NS3 mutations in haemophiliacs. Haemophilia 2014; 20: 659-65.

  26. Beloukas A, King S, Childs K, Papadimitropoulos A, Hopkins M, Atkins M, Agarwal K, et al. Detection of the NS3 Q80K polymorphism by sanger and deep sequencing in hepatitis C virus (HCV) genotype 1a strains in the united kingdom. Clinical Microbiology and Infection 2015; pii: S1198- 743X(15)00734-X.

  27. Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, et al. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther 2015; 20: 199-208.

  28. McCormick AL, Moynihan L, Macartney MJ, Garcia-Diaz A, Smith C, Johnson MA, Rodger AJ, et al. Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. Antivir Ther 2015; 20: 361-3.

  29. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, et al. Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies. Gut 2015; 64: 1824-33.

  30. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C 2015.

  31. Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PloS one 2015; 10: e0134395.

  32. Tan S, He Y. Hepatitis C: Antiviral drug discovery and development. Horizon Scientific Press; 2011.




2020     |     www.medigraphic.com